Zedace

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

Captopril

Dostępny od:

Alphapharm Pty Ltd

Klasa:

Medicine Registered

Ulotka dla pacjenta

ZEDACE
1
ZEDACE
_contains the active ingredient captopril_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Zedace.
It does not contain all of the
available information.
It does not take the place of talking
to your doctor or pharmacist.
All medicines have benefits and
risks.  Your doctor has weighed the
risks of you taking Zedace against
the benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT ZEDACE IS USED
FOR
Zedace is used to treat:
*
high blood pressure
(hypertension)
*
heart failure
*
kidney problems in some people
who have type 1 or
insulin-dependent diabetes.
It is also used to improve the survival
of some people who have had a heart
attack.
Zedace belongs to a group of
medicines called angiotensin
converting enzyme (ACE) inhibitors.
ACE inhibitors lower blood pressure
by widening blood vessels, making it
easier for the heart to pump blood
around the body.
Widening of the blood vessels also
increases the supply of blood and
oxygen to the heart.  This allows
your heart to cope better when you
place extra demands on it, such as
during exercise, so you may not get
short of breath as easily (if you have
heart failure).
By increasing the supply of oxygen
to your heart, your heart does not
have to work as hard, which may
reduce the risk of further damage to
the heart after a heart attack.
Zedace also improves blood flow
through the kidneys, and as a result
helps to slow down the kidney
damage caused by type 1
insulin-dependent diabetes.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY THIS MEDICINE
HAS BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed it
for another reason.
ZEDACE IS NOT RECOMMENDED FOR USE
IN CHILDREN.
Safety and effectiveness of Zedace in
children have not been clearly
esta

Charakterystyka produktu

ZEDACE
_Captopril_ 

PRODUCT INFORMATION 

NAME OF THE MEDICINE

Active ingredient:  Captopril  

Chemical name:  1-[(2S)-3-mercapato-2-methyl-propionyl]-L-proline  

Structural formula: 

Molecular formula:  C
9
H
15
NO
3
S  

Molecular weight:   217.3 

CAS Registry No.:  62571-86-2 

DESCRIPTION

Captopril is a white to almost white, crystalline powder. 

Each Zedace 12.5, 25 and 50 tablet contains 12.5 mg, 25 mg and 50
mg of captopril, respectively. 
Zedace tablets also contain cellulose - microcrystalline, starch -
maize, lactose anhydrous, stearic acid and 
sodium starch glycollate. 

CLINICAL PHARMACOLOGY

It is a highly specific competitive inhibitor of angiotensin I
converting enzyme, the enzyme responsible for the 
conversion of angiotensin I to angiotensin II. 

The mechanism of action of
captopril has not yet been fully elucidated, however its
beneficial effects in 
hypertension and heart failure appear to result mainly through
suppression of the rennin-angiotensin-aldosterone 
system.  However, there is no consistent correlation between plasma
renin levels and response to captopril.  
Renin, an enzyme synthesised by the kidneys, is released into the
circulation where it acts on a plasma globulin 
substrate to produce angiotensin I, a relatively inactive
decapeptide.  Angiotensin I is then converted 
enzymatically by angiotensin-converting enzyme (ACE) to the
octapeptide angiotensin II, one of the most potent 
endogenous vasoconstrictor substances.  Angiotensin II also
stimulates aldosterone secretion from the adrenal 
cortex, thereby contributing to sodium and fluid retention and
potassium loss. 

Captopril prevents the conversion of angiotensin I to
angiotensin II by inhibition of ACE, a peptidyldipeptide 
carboxyhydrolase.  This is reflected by a decrease in the pressor
substance, angiotensin II, and an increase in 
plasma renin a